ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate

Abstract

Background Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles.

Aim To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer.

Materials and Methods In the case-control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate.

Results No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 (p < 0.001), A1 (p < 0.001), and B (p = 0.013), and a lower proportion of metastatic disease in A2 (0%, p = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, p < 0.001), A1 (70.1%, p = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, p < 0.001), O2 (100%, p = 0.045), and recurrent tumors in patients with O1 (70.2%, p < 0.001) and A1 (74.2%, p = 0.007) alleles.

Conclusion We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively.

Keywords

ABO blood groups / urinary bladder cancer / ABO phenotype / ABO genotype / ABO allele / case-control study

References

[1] McCormick B, Dahmen A, Antar A, Baumgarten A, Dhillon J, Spiess PE. Rare urologic tumors. Curr Opin Urol 2017; 27(01) 68-75

[2] Rummel SK, Ellsworth RE. The role of the histoblood ABO group in cancer. Future Sci OA 2016;2(02) FSO107

[3] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(06) 394-424

[4] Veskimäe E, Espinos EL, Bruins HM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol 2019; 2(06) 625-642

[5] Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306(07) 737-745

[6] Kurth KH, Schellhammer PF, Okajima E, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol 1995; 2(Suppl. 02) 8-22

[7] American Joint Committee on Cancer. AJCC Cancer Staging Manual. American Joint Committee on Cancer; 2017

[8] Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(03) 466-5 , discussion 475-477

[9] Hautmann RE, Abol-Enein H, Hafez K, et al; World Health Organization (WHO) Consensus Conference on Bladder Cancer. Urinary diversion. Urology 2007; 69(1, Suppl): 17-49

[10] Owen R. Karl Landsteiner and the first human marker locus. Genetics 2000; 155(03) 995-998

[11] Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature 1990; 345(6272) 229-233

[12] Yamamoto F, Marken J, Tsuji T, White T, Clausen H, Hakomori S. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc α 1—2Gal α 1—3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem 1990; 265(02) 1146-1151

[13] Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol 2004; 41(02) 93-117

[14] Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999; 1473(01) 247-266

[15] Patnaik SK, Helmberg W, Blumenfeld OO. BGMUT database of allelic variants of genes encoding human blood group antigens. Transfus Med Hemother 2014; 41(05) 346-351

[16] Pereira V, Gusmão L. X-chromosome markers. Encyclopedia of Forensic Sciences, 2nd ed. January 1, 2013: 257-263

[17] Westhoff CM. Blood group genotyping. Blood 2019; 133(17) 1814-1820

[18] Teoh JYC, MacLennan S, Chan VWS, et al. An International Collaborative Consensus Statement on en bloc resection of bladder tumour incorporating two systematic reviews, a two-round Delphi survey, and a consensus meeting. Eur Urol 2020; 78(04) 546-569

[19] Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19(03) 666-675

[20] Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 2017

[21] Brierley J, Gospodarowicz MD, Wittekind CT. TNM Classification of Malignant Tumors International Union Against Cancer, 8^th ed. Oxford, England: Wiley; 2017: 57-62

[22] Gassner C, Schmarda A, Nussbaumer W, Schönitzer D. ABO glycosyltransferase genotyping by polymerase chain reaction using sequence-specific primers. Blood 1996; 88(05) 1852-1856

[23] Yamamoto F. Molecular genetics of the ABO histo-blood group system. Vox Sang 1995; 69(01) 1-7

[24] Yu H, Xu N, Li ZK, et al. Association of ABO blood groups and risk of gastric cancer. Scand J Surg 2020; 109(04) 309-313

[25] Ghazarian H, Idoni B, Oppenheimer SB. A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 2011; 113(03) 236-247

[26] Cartron JP, Colin Y. Structural and functional diversity of blood group antigens. Transfus Clin Biol 2001; 8(03) 163-199

[27] Orlow I, Lacombe L, Pellicer I, et al. Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. Int J Cancer 1998; 75(06) 819-824

[28] Foresto P, Biondi C, Brufman A, et al. Deleción antigénica ABH en células de sedimento urinario de pacientes con adenoma de próstata. Arch Esp Urol 2000; 53(09) 770-773

[29] Joh HK, Cho E, Choueiri TK. ABO blood group and risk of renal cell cancer. Cancer Epidemiol 2012; 36(06) 528-532

[30] Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 2010; 70(03) 1015-1023

[31] Srinivas V, Khan SA, Hoisington S, Varma A, Gonder MJ. Relationship of blood groups and bladder cancer. J Urol 1986; 135(01) 50-52

[32] Orihuela E, Shahon RS. Influence of blood group type on the natural history of superficial bladder cancer. J Urol 1987; 138(04) 758-759

[33] Yang H, Yan J. A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. Medicine (Baltimore) 2022; 101(39) e30893

[34] D'Andrea D, Moschini M, Soria F, et al. ABO blood group and rhesus factor are not associated with outcomes after radical cystectomy for non-metastatic urothelial carcinoma of the bladder. Anticancer Res 2017; 37(10) 5747-5753

[35] Engel O, Soave A, Peine S, et al. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol 2015; 33(11) 1769-1776

[36] Deng N, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 2017; 8(66) 110635-110649

[37] Brody T. Biomarkers. Clin Trials 2016; 377-419

[38] Ben Nasr H, Hamrita B, Batbout M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter -160 C/A is associated with risk of nasopharyngeal cancer. Clin Chim Acta 2010; 411(17-18): 1253-1257

[39] Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004; 64(11) 3871-3877

[40] Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C. Silent (synonymous) SNPs: should we care about them?. Methods Mol Biol 2009; 578: 23-39

[41] Tennessen JA, Bigham AW, O'Connor TD, et al; Broad GO, Seattle GO, NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012; 337(6090) 64-69

[42] Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41(09) 986-990

RIGHTS & PERMISSIONS

2024 Global Medical Genetics